Pibrentasvir

Pibrentasvir is an NS5A inhibitor antiviral agent.^[1] In the United States and Europe, it is approved for use with glecaprevir as the combination drug glecaprevir/pibrentasvir (trade name Mavyret in the US and Maviret in the EU) for the treatment of hepatitis C.^[2][3] It is sold by Abbvie.^{[citation needed]}

Trade namesMavyret, Maviret (combination with glecaprevir)

Other namesABT-530

Protein binding>99.9%

Elimination half-life13 hours

Quick facts Clinical data, Trade names ...

Pibrentasvir

Clinical data
Trade names	Mavyret, Maviret (combination with glecaprevir)
Other names	ABT-530
Pharmacokinetic data
Protein binding	>99.9%
Elimination half-life	13 hours
Excretion	96.6% in faeces
Identifiers
IUPAC name Methyl {(2S,3R)-1-[(2S)-2-{5-[(2R,5R)-1-{3,5-difluoro-4-[4-(4-fluorophenyl)-1-piperidinyl]phenyl}-5-(6-fluoro-2-{(2S)-1-[N-(methoxycarbonyl)-O-methyl-L-threonyl]-2-pyrrolidinyl}-1H-benzimidazol-5-yl)-2-pyrrolidinyl]-6-fluoro-1H-benzimidazol-2-yl}-1-pyrrolidinyl]-3-methoxy-1-oxo-2-butanyl}carbamate
CAS Number	1353900-92-1
PubChem CID	58031952
DrugBank	DB13878
ChemSpider	35013016
UNII	2WU922TK3L
KEGG	D10816
CompTox Dashboard (EPA)	DTXSID601027946
ECHA InfoCard	100.264.922
Chemical and physical data
Formula	C57H65F5N10O8
Molar mass	1113.201 g·mol−1
3D model (JSmol)	Interactive image
SMILES C[C@H]([C@@H](C(=O)N1CCC[C@H]1c2[nH]c3cc(c(cc3n2)[C@H]4CC[C@@H](N4c5cc(c(c(c5)F)N6CCC(CC6)c7ccc(cc7)F)F)c8cc9c(cc8F)[nH]c(n9)[C@@H]1CCCN1C(=O)[C@H]([C@@H](C)OC)NC(=O)OC)F)NC(=O)OC)OC
InChI InChI=1S/C57H65F5N10O8/c1-29(77-3)49(67-56(75)79-5)54(73)70-19-7-9-47(70)52-63-41-25-35(37(59)27-43(41)65-52)45-15-16-46(72(45)34-23-39(61)51(40(62)24-34)69-21-17-32(18-22-69)31-11-13-33(58)14-12-31)36-26-42-44(28-38(36)60)66-53(64-42)48-10-8-20-71(48)55(74)50(30(2)78-4)68-57(76)80-6/h11-14,23-30,32,45-50H,7-10,15-22H2,1-6H3,(H,63,65)(H,64,66)(H,67,75)(H,68,76)/t29-,30-,45-,46-,47+,48+,49+,50+/m1/s1 Key:VJYSBPDEJWLKKJ-NLIMODCCSA-N

Close

ibrentasvir is a pangenotypic direct-acting antiviral that targets the hepatitis C virus (HCV) NS5A protein, which plays a key role in viral RNA replication and virion assembly.^[4]. It is active against multiple HCV genotypes and has demonstrated high efficacy when used in combination with glecaprevir, contributing to sustained virologic response rates across diverse patient populations.^[5]